3-Ethylsulfanylpyrrolidine-2,5-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-Ethylsulfanylpyrrolidine-2,5-dione
• 英文别名: 3-ethylsulfanylpyrrolidine-2,5-dione
• 化学式: C₆H₉NO₂S
• 分子量: 159.21
• InChiKey: WOHYPYYNBGFAAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF<br/>[FR] POLYMÈRES MODIFIÉS EN EXTRÉMITÉ ET LEURS CONJUGUÉS
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014008375A1

  公开（公告）日：2014-01-09

  A terminally modified polymer is provided herein. At least one terminus of the polymer is -O-(CH2)2-LM or -O-CH2-CH(OH)-CH2-CR1=CR2R3. LM, R1, R2, and R3 are defined herein Also disclosed are terminal conjugates comprising the polymer and a pharmaceutically useful modifier, as well as compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种终端修饰的聚合物。聚合物的至少一个末端是-O-(CH2)2-LM或-O- -CH(OH)- -CR1=CR2R3。LM、R1、R2和R3在此处有定义。还披露了包括聚合物和药用修饰剂的终端共轭物，以及包括这些共轭物的组合物、它们的制备方法以及使用这些共轭物或它们的组合物治疗各种疾病的方法。
• LIGAND-TARGETED MOLECULES AND METHODS THEREOF
  申请人：INVICTUS ONCOLOGY PVT.LTD.

  公开号：US20150045428A1

  公开（公告）日：2015-02-12

  The present invention relates to ligand-targeted molecules and ligand drug conjugates (LDCs) comprising a ligand connected to a functional group, which is connected to a linker, which in turn is bonded to a drug. The LDCs of the present invention also comprise platinum coordination complex wherein the platinum is connected to the linker through monocarboxylato and O→Pt coordinate bonds. The present invention also relates to methods for preparing these ligand drug conjugates. The present invention further relates to methods for the treatment of tumours using the ligand drug conjugates of the present invention.

  本发明涉及配体靶向分子和配体药物结合物（LDCs），其中配体连接到功能基团，功能基团连接到连接剂，连接剂又与药物结合。本发明的LDCs还包括铂配位络合物，其中铂通过单羧酸盐和O→Pt配位键与连接剂连接。本发明还涉及制备这些配体药物结合物的方法。本发明还涉及使用本发明的配体药物结合物治疗肿瘤的方法。
• [EN] ANTIBODY CONJUGATES OF TOLL-LIKE RECEPTOR AGONISTS<br/>[FR] CONJUGUÉS D'ANTICORPS D'AGONISTES DE RÉCEPTEURS DE TYPE TOLL
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2020056192A1

  公开（公告）日：2020-03-19

  Imidazoquinoline compounds of formula (IA), conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed imidazoquinoline compounds are useful, among other things, in the treating of cancer and modulating TLR7. Additionally, imidazoquinoline compounds incorporated into a conjugate with an antibody construct are described herein.

  本文披露了用于治疗疾病，如癌症的化合物（IA）的咪唑喹啉类化合物、结合物和药物组合物。所披露的咪唑喹啉类化合物在治疗癌症和调节TLR7等方面具有用途。此外，本文还描述了将咪唑喹啉类化合物与抗体构造物结合的共轭物。
• COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY
  申请人：Endocyte, Inc.

  公开号：EP3777898A2

  公开（公告）日：2021-02-17

  Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.

  本文描述了利用正电子发射断层扫描诊断和/或监测致病性疾病的化合物、组合物和方法。还描述了式 B-L-P 的共轭物，其中 B 是选自维生素受体结合配体（如叶酸）、PSMA 结合配体或 PSMA 抑制剂的靶向药的基团；L 是由天冬氨酸、赖氨酸或精氨酸组成的二价连接体，P 是成像剂或放疗剂的基团，如放射性核素或含放射性核素的基团，或能结合放射性核素的化合物的基团，如金属螯合基团。
• Butyrylcholinesterase zwitterionic polymer conjugates
  申请人：Kodiak Sciences Inc.

  公开号：US10363290B2

  公开（公告）日：2019-07-30

  The present invention provides recombinant butyrylcholinesterase fusion proteins, including Fc fusion proteins and multi-armed high MW polymers containing hydrophilic groups conjugated to the fusion proteins, and methods of preparing such polymers.

  本发明提供了重组丁酰胆碱酯酶融合蛋白，包括 Fc 融合蛋白和与融合蛋白共轭的含有亲水基团的多臂高分子量聚合物，以及制备此类聚合物的方法。